Drug Development

Synthetic Peptide Bars Door to HIV Entry

Published in Vaccine Weekly, June 26th, 1995

A new synthetic peptide has at least two mechanisms of action that prevent HIV from entering CD4⁺ and CD4^- cells.

The peptide, SPC3, is a type of multibranched polymer - dubbed synthetic polymeric constructions or SPCs - originally developed as a means of making peptide-based vaccines more immunogenic.

But SPC3, which contains eight consensus motifs from the V3 loop of HIV-1, does not induce an immune response.

"This peptide has broad anti-HIV activity in CD4⁺ lymphocytes and macrophages and CD4^-/GalCer⁺ epithelial cells," noted researchers Nouara Yahi and colleagues of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-06-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry